HRV by Age: What Is a Good Heart Rate Variability for Your Age?

Seeing your heart rate variability score for the first time can create more questions than answers. Is 25 milliseconds low? Is 60 good? Should your score match other people of the same age?

Understanding HRV by age provides useful context because heart rate variability generally decreases with age. However, age is only one part of the picture. Gender, fitness, sleep, stress, medication, illness, and the way your device calculates HRV can all influence the number you see.

This article explains what HRV measures, how typical values differ across age groups and why your personal trend often matters more than comparison with a population average.

It also explores how lifestyle factors and more structured approaches to autonomic support may influence the pathways connected to HRV. Later in the article, we consider Nurosym, a non-invasive auricular vagus nerve stimulation wearable designed to move beyond passive tracking and actively support vagal regulation.

What Does HRV Measure?

Heart rate variability describes the small differences in time between consecutive heartbeats.

Although a resting heart rate may appear steady, the interval between one beat and the next naturally changes. For example, your heart may beat after 830 milliseconds, then 870 milliseconds, then 845 milliseconds. These variations are measured in milliseconds and analysed to produce an HRV score.

HRV is influenced by the autonomic nervous system, which helps regulate functions including heart rate, breathing, digestion, circulation and recovery.

Its two main branches are:

• the sympathetic nervous system, which helps mobilise the body during activity or stress;

• the parasympathetic nervous system, which supports rest, digestion and recovery.

The vagus nerve is a major parasympathetic pathway. Higher resting HRV is often associated with greater parasympathetic influence and physiological adaptability, although a single high or low value cannot independently establish whether someone is healthy.

Why Does HRV Change With Age?

HRV is usually highest during childhood and early adulthood before gradually declining across the lifespan.

This reflects several age-related changes, including alterations in autonomic regulation, cardiovascular function, physical activity, recovery capacity and the responsiveness of the heart to vagal signalling.

In the Lifelines Cohort Study, researchers analysed resting electrocardiogram data from more than 84,000 people without selected cardiovascular and metabolic conditions. Median RMSSD declined steadily from adolescence until approximately 60 years of age, after which the pattern became more stable.

This does not mean that lower HRV in later life automatically indicates poor health. A value that would be unusually low for someone aged 25 may be relatively typical for someone aged 65.

Age-based data can provide context, but it should never be treated as a pass-or-fail test.

HRV Chart by Age and Gender

The following HRV chart by age shows median RMSSD values from the Lifelines Cohort Study. RMSSD is a commonly used HRV measure that is particularly sensitive to short-term parasympathetic influences on heart rhythm.

 

Values are median RMSSD measurements derived from short resting electrocardiograms. They provide population-level reference points rather than diagnostic cut-offs or targets that every person should aim to reach.

The table shows the broad age-related pattern, but it also hides considerable variation. Within every age group, healthy participants had values both substantially above and below the median.

This is why the average HRV by age should be used as orientation rather than as an ideal score everyone should attempt to reach.

What Is a Good HRV by Age?

A good HRV is one that is appropriate for your age, measurement method and personal physiology, and remains reasonably stable or improves alongside positive changes in sleep, recovery and overall health.

As a broad guide using resting RMSSD:

• values around 40–60 ms are relatively common among healthy younger adults;

• values around 25–40 ms are frequently seen during middle age;

• values in the high teens or twenties may be typical in adults over 60.

These ranges should not be compared directly with values generated through another HRV metric or collected under different conditions.

A 30 ms overnight RMSSD reading, for example, is not equivalent to a 30 ms SDNN value captured by a smartwatch during a brief daytime measurement.

The question is therefore less about whether one number is universally “good” and more about whether the reading makes sense in context.

Why HRV Metrics Cannot Always Be Compared

One of the most common sources of confusion is that wearables do not all calculate HRV in the same way.

RMSSD

RMSSD measures short-term differences between consecutive heartbeat intervals. It is commonly used for overnight or short resting measurements and is sensitive to parasympathetic activity.

Oura Ring, for example, calculates average overnight HRV from repeated five-minute RMSSD samples collected throughout sleep.

SDNN

SDNN measures overall variation across the recording period. It is frequently used in clinical electrocardiography and is also the HRV metric commonly displayed in Apple Health.

The result depends heavily on recording length. SDNN measured over five minutes cannot be interpreted in the same way as SDNN calculated from a 24-hour Holter recording.

Measurement timing

HRV may be recorded:

• during sleep

• immediately after waking

• during a short breathing session

• periodically throughout the day

• across a full 24-hour clinical recording

Movement, posture, meals, breathing and emotional stimulation can all alter daytime readings. Overnight data often provide a more stable comparison because the measurement is collected during a relatively consistent physiological state.

Before using any normal HRV by age table, check which metric and measurement period the source uses.

Average Sleeping HRV by Age

Average sleeping HRV also tends to decline with age, although the precise values vary between wearable platforms and populations.

Overnight measurements are often higher and more stable than isolated daytime readings because parasympathetic activity usually becomes more prominent during sleep. However, sleep-stage distribution, waking episodes, alcohol, late meals, illness and bedroom temperature can all affect the nightly result.

Large-scale wearable research involving more than 25,000 adults found that overnight RMSSD generally declined from early adulthood into midlife, with some levelling or slight increase in older age groups. Sleep duration and physical activity were also strongly associated with the results.

The most useful way to interpret average sleeping HRV is to:

1. Use the same device consistently

2. Establish a baseline across several weeks

3. Compare similar nights rather than isolated readings

4. Look for patterns alongside sleep, training, stress and illness

One unexpectedly low night is usually less informative than a sustained change from your normal pattern.

HRV by Age and Gender

Research indicates that HRV can vary gender, although the direction and size of the difference depend on the metric, age and recording method.

In the Lifelines resting ECG data, women generally had higher median RMSSD values than men from early adulthood into middle age, with the difference becoming smaller later in life.

Other studies have also found gender-related differences in autonomic measures, although hormonal status, resting heart rate, fitness, body composition and measurement conditions complicate direct comparisons.

For women, HRV may also fluctuate across the menstrual cycle. Pregnancy and the menopausal transition can introduce further physiological changes.

What Can Temporarily Lower HRV?

A lower reading does not necessarily mean that something is wrong. HRV is responsive to short-term physiological load and may fall after:

• poor or shortened sleep

• alcohol consumption

• intense exercise or insufficient recovery

• psychological stress

• infection or emerging illness

• dehydration

• long-distance travel or disrupted routines

• a late or unusually heavy meal

• certain medicines

• hormonal changes

These influences are part of what makes HRV useful. A downward trend may reveal that the body is carrying more strain than usual, even before the cause feels obvious.

The reading becomes more meaningful when it corresponds with other signs, such as fatigue, disrupted sleep, reduced exercise performance, a higher resting heart rate or difficulty recovering after stress.

Is Higher HRV Always Better?

Higher HRV is generally associated with stronger autonomic flexibility when measured under consistent resting conditions. However, higher is not always automatically better.

Unusually elevated or erratic values can sometimes reflect measurement artefacts, irregular heart rhythms or poor-quality signal detection. Large sudden changes deserve closer attention, particularly when accompanied by palpitations, dizziness, chest discomfort, fainting or shortness of breath.

The goal should not be to maximise HRV at any cost. A more useful aim is to support a stable and responsive autonomic pattern that is appropriate for your age and physiology.

How to Support a Healthy HRV by Age

Age-related change is normal, but HRV is also influenced by modifiable aspects of health and daily routine.

Build consistent sleep

Regular sleep and waking times help create a predictable recovery rhythm. Reducing alcohol, late meals, bright light and intense work close to bedtime may also support overnight HRV.

Balance exercise and recovery

Aerobic activity, strength training and regular movement can support cardiovascular and autonomic health. Training should be matched with adequate rest, particularly when HRV, sleep quality and energy are all trending downwards.

Use slower breathing

Slow, comfortable breathing can influence respiratory rhythm and cardiac vagal activity. A practical approach is to inhale gently for around four seconds and exhale for approximately six seconds without forcing the breath.

Address the source of physiological strain

Rather than attempting to increase HRV as an isolated score, consider what may be suppressing it. Poor sleep, illness, under-fuelling, sustained stress and excessive alcohol are more meaningful targets than the number itself.

Follow the trend

Measure under similar conditions and look at seven-day or longer-term patterns. This reduces the temptation to overreact to routine daily variation.

From Tracking HRV to Supporting Autonomic Regulation

Wearables can show when HRV changes, but they do not necessarily influence the physiological pathways behind the reading.

For people seeking a more active and repeatable form of nervous system support, non-invasive vagal neuromodulation provides a different approach. Nurosym uses proprietary Auricular Vagal Neuromodulation Technology, or AVNT™, to deliver controlled electrical stimulation through the auricular branch of the vagus nerve at the ear.

Developed by Parasym through more than ten years of research, Nurosym is supported by over 60 completed studies and more than 100 ongoing studies. It is designed to complement the foundations that influence HRV, including sleep, movement, nutrition and recovery, by providing a structured method of supporting vagal pathways within a consistent daily routine.

Clinical Evidence for Nurosym and Autonomic Regulation

Research using Parasym’s AVNT™ technology has examined direct measures of vagal activity and HRV, as well as several physiological outcomes closely linked to autonomic regulation.

Reported findings include:

• 61% increase in vagus nerve activity, measured through high-frequency power (HF power)

• 18% increase in heart rate variability, measured using RMSSD

• 45% improvement in an HRV measure associated with autonomic regulation, based on the HF/LF ratio used in the study

These findings are particularly relevant in the context of HRV because they assess measurable changes in cardiac autonomic activity rather than relying only on subjective reports.

30% Improvement in Sleep and 48% Reduction in Fatigue

Sleep quality and fatigue can both influence HRV and the body’s capacity to recover from physiological strain.

Across studies using Parasym’s AVNT™ technology, reported outcomes include:

• 30% improvement in sleep quality, measured using the Pittsburgh Sleep Quality Index

• 48% reduction in fatigue

These findings suggest that the research extends beyond an isolated HRV measurement to outcomes that may reflect the wider recovery environment in which autonomic regulation takes place.

78% Reduction in IL-6 and 28% Reduction in Oxidative Stress

Vagal pathways also interact with inflammatory and oxidative processes, which may influence cardiovascular function, recovery and autonomic stability.

Reported findings include:

• 78% reduction in IL-6

• 23% reduction in TNF-α

• 28% reduction in oxidative stress

Cardiovascular and Circulatory Findings

Research has also examined cardiovascular outcomes associated with autonomic and circulatory regulation.

Some of the reported findings include:

• 45% reduction in postural heart-rate abnormalities

• 52% reduction in blood-pressure variability

• 10% reduction in diastolic blood pressure

• 50% improvement in blood-vessel flexibility

• 64% improvement in microcirculation markers

These outcomes were measured in different studies involving different participant groups and protocols. They provide broader context for the role of AVNT™ in cardiovascular and autonomic research, rather than representing expected outcomes for every user.

Safety and Tolerability

Safety and tolerability have also been assessed in clinically complex populations. A retrospective analysis covering more than 200 cardiovascular participants across several studies reported no device-related serious adverse events to date. Minor effects were uncommon and limited to temporary tingling at the ear in a small number of participants.

Nurosym should be used according to the product guidance. People who have an implanted electronic device, a significant cardiovascular or neurological condition, or unexplained symptoms should seek advice from an appropriate healthcare professional before use. As safety has not been established across all populations, Nurosym is not recommended for children or during pregnancy.

When Should a Low HRV Be Discussed With a Healthcare Professional?

A low HRV reading alone does not diagnose a medical condition.

Professional assessment is appropriate when a persistent change is accompanied by symptoms such as:

• fainting or recurrent dizziness

• an irregular or unusually rapid heartbeat

• chest pain

• breathing difficulty

• unexplained exercise intolerance

• marked or persistent fatigue

• new neurological symptoms

Wearable data can provide useful supporting information, but it should not replace electrocardiography or an appropriate clinical assessment when symptoms suggest an underlying health issue.

HRV by Age: The Key Takeaways

HRV generally becomes lower with age, making age-based reference values useful when interpreting a score. Median resting RMSSD commonly falls from approximately 40–50 ms in early adulthood to around 20 ms or below later in life, although the range within every age group remains wide.

The metric, device and timing matter just as much as the number. An overnight RMSSD reading cannot be compared directly with daytime SDNN or a 24-hour clinical recording.

The most reliable benchmark is therefore your own trend, measured consistently and interpreted alongside sleep, stress, exercise, illness and how you feel.

For people who want to move beyond passive measurement, Nurosym offers a research-led form of auricular vagal neuromodulation designed to support autonomic regulation as part of a consistent daily routine. Developed through more than a decade of research and used across more than five million user sessions worldwide, it provides a structured way to translate insight from HRV tracking into active nervous system support.

Disclaimer: Nurosym is a CE-marked medical device in Europe. The clinical research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions, some of which include populations outside of the device’s primary indication. Individual results may vary. All percentage figures cited reflect findings from specific study populations and should not be interpreted as a medical claim, and cannot guarantee outcomes for all users. Individuals should consult a qualified health professional regarding their personal health needs.

References:

1. Dalle Luche R, et al. First report of safety and tolerability of low-level tragus vagal neuromodulation in cardiovascular patients. J Am Coll Cardiol. 2024.

2. Geng Y, et al. Circadian stage-dependent and stimulation duration effects of transcutaneous auricular vagus nerve stimulation on heart rate variability. PLoS One. 2022.

3. Maestri R, et al. Impact of optimized transcutaneous auricular vagus nerve stimulation on cardiac autonomic profile in healthy subjects and heart failure patients. Physiol Meas. 2024.

4. Molaeizadeh G, et al. Effects of transcutaneous vagus nerve stimulation, neurofeedback, and their combination on cortisol, anxiety, and depression subtypes in non-clinical adults. 2025.

5. Stavrakis S, et al. TREAT AF — transcutaneous electrical vagus nerve stimulation to suppress atrial fibrillation: a randomised clinical trial. JACC Clin Electrophysiol. 2020.

6. Stavrakis S, et al. Noninvasive vagus nerve stimulation in postural tachycardia syndrome: a randomized clinical trial. JACC Clin Electrophysiol. 2023.

7. Dasari TW, et al. Effects of low-level tragus stimulation on endothelial function in heart failure with reduced ejection fraction. J Card Fail. 2021;27(5).

8. Dasari TW, et al. Noninvasive low-level tragus stimulation attenuates inflammation and oxidative stress in acute heart failure. Clin Auton Res. 2023.

9. Mbikyo E, et al. Low-level tragus stimulation attenuates blood pressure in young individuals with hypertension: results from a small-scale single-blind controlled randomized clinical trial. J Am Heart Assoc. 2024.

10. Zheng Y, et al. Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study. Front Neurol. 2024.

11. Verbanck P, et al. Transcutaneous auricular vagus nerve stimulation (tVNS) can reverse the manifestations of the Long-COVID syndrome: a pilot study. Adv Neurol Neurosci Res. 2021.

12. Natelson B, Blate M, Soto T. Transcutaneous vagus nerve stimulation for long COVID and chronic fatigue symptoms. medRxiv. 2022.

13. Dolcini J, et al. Vagal nerve stimulation and fibromyalgia: an additional therapeutic option. Clin Exp Rheumatol. 2025.

14. Jackowska M, et al. Effects of transcutaneous vagus nerve stimulation on subthreshold affective symptoms and perceived stress: findings from a single-blinded randomized trial in community-dwelling adults. 2025.

15. Kamboj SK, et al. Electroceutical enhancement of self-compassion training using transcutaneous vagus nerve stimulation: results from a preregistered fully factorial randomized controlled trial. Psychol Med. 2025.

 

Retour au blog